• AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021
• The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China
• A recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world and 1^st  in China for the number of clinical samples analyzed amongst companies that offer next-generation early cancer screening and detection technology

AnPac Bio-Medical Science (NASDAQ: ANPC) recently held its 2021 technical symposium entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment.” The symposium was held in Shanghai, China, and was attended by life science Fortune 500 companies such as Thermo Fisher Scientific and Roche Pharmaceuticals. Experts came together to discuss emerging cancer prevention and treatment theories and technologies, including the applications of biophysical technology to address these needs. Measurement of biophysical properties is the basis for Anpac Bio’s novel CDA technology. The Company’s CDA technology can rapidly detect 26 different types of cancers with a simple blood test. Talking points of the symposium included the newly announced cooperation between AnPac Bio and Roche Pharmaceutical China, as well as Thermo Fisher Scientific’s latest developments in in-vitro diagnosis (“IVD”), and the clinical trials that have been held on AnPac Bio’s proprietary cancer differentiation analysis (“CDA”) technology, including recently unblinded and analyzed clinical data. AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter, and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical properties and has achieved significant results. In 2019, Frost & Sullivan ranked AnPac Bio third in the world and first in China among those companies in the region in terms of the number of clinical samples offering next-generation early cancer screening and detection. With one of the largest sample libraries in the world and more than 220,000 samples tested, AnPac Bio is an innovative leader in the field. The company’s CDA technology has shown to be advantageous over traditional detection methods, allowing it to outperform in the early detection market. The company’s main goal for 2021 is to extend its major discoveries in the field of early cancer detection and also develop cancer treatment technologies. “This technical symposium allowed people to better understand the most cutting-edge applications of biophysical technology in cancer prevention and treatment, and it also played an important role in promoting future research and development in cancer prevention and treatment,” Dr. Chris Yu, CEO and Chairman of AnPac Bio, said. “As a pioneer in the application of biophysics to cancer prevention and treatment, AnPac Bio continues to report new ideas and cutting-edge technology to the public, sharing the latest clinical study and trial results, and continuing to promote collaborations between industry, and academia.” AnPac Bio has proven to be an early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. The company’s patent applications and IP began in the early 2010’s, and by 2014 it had already announced a cancer screening product with the capability of screening 16 types of cancer earlier than anyone else in the industry. AnPac Bio’s CDA technology combines the assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead up to serious health conditions (including cancer). The technology can also be used to pinpoint the most likely location for cancer or predict where the risk will be high in the future. Having invented and championed the idea and method of “multi-level, multi-parameter” cancer screening, AnPac Bio’s contributions are now recognized and accepted by leading United States medical institutions and life science companies. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing
• DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since January 2017
• The technology is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions
• DehydraTECH-enabled drugs offer multiple benefits, including faster delivery, increased bioavailability, increased brain absorption, improved drug potency, reduced administration costs, and masking unwanted taste without the use of additional sweeteners.

As an innovator of drug delivery methods, Lexaria Bioscience (NASDAQ: LEXX) and its patented DehydraTECH are improving the speed and efficiency of orally delivered fat-soluble active molecules and drugs. Lexaria Bioscience is advancing its IP for transforming existing consumer products and medications that may improve availability and bioavailability. DehydraTECH promotes a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing. Lexaria Bioscience operates four subsidiary companies focused on different commercial opportunities within their respective industries – Lexaria Pharma Corp., Lexaria Nicotine Corp. (16.67% owned by Altria Ventures Inc.), Lexaria Hemp Corp., and Lexaria Canpharm Corp. The DehydraTECH technology is also sub-licensed to other companies in select countries. The Company also has a collaborative research agreement with the National Research Council (“NRC”), Canada’s premier research and technology organization. Lexaria Pharma Corp. – investigates new products for high blood pressure (hypertension), antiviral therapy, and other drug classes. Lexaria Nicotine Corp. – investigates oral non-combusted tobacco-derived nicotine product formats. Lexaria Hemp Corp. – pursues business-to-business (“B2B”) opportunities, with cannabinoids like cannabidiol (“CBD”). Lexaria Canpharm Corp. – operates a state-of-the-art Health Canada-licensed laboratory that can develop novel psychotropic cannabinoid formulations for commercialization in sectors where it is federally legal. The DehydraTECH technology is suitable for use with a wide range of product formats. These include pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions. The technology was specifically designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients into a more easily absorbable format, allowing them to enter the bloodstream more quickly and effectively. The use of DehydraTECH-enabled drugs or consumer products offers the following benefits:

• Speeds up delivery: effects can be felt by consumers in a matter of minutes
• Increases bioavailability: more effective at delivering drug or product into the consumer’s bloodstream
• Increases brain absorption: animal testing has suggested significant improvement in the quality of the drug delivered across the blood-brain barrier
• Improves drug potency: more of the ingested product is made available to the body, requiring lower dosages to achieve the desired effects
• Reduces drug administration costs: lower dosages mean overall lower drug costs
• Masks unwanted taste: technology eliminates or reduces the need for sweeteners

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reducing the onset time from one to two hours to just minutes – masking unwanted tastes. The technology will be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), and nicotine. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Sustainability cultivator Ideanomics has reached an agreement with commercial EV vehicle manufacturer VIA Motors to acquire VIA in an all-stock transaction valued at $450 million
• The VIA acquisition will solidify Ideanomics’ position as a made-in-America brand focused on building an end-to-end commercial EV ecosystem
• Ideanomics has completed other M&A activity in recent months designed to establish sustainable solutions that reduce the harmful effects of pollutants on the earth’s climate, particularly involving wireless battery-charging technology for commercial fleets
• The acquisition will help VIA to focus on completing the manufacturing process, with vehicles expected to roll out by 2023

New York-based Ideanomics (NASDAQ: IDEX) has been making a name for itself as a commercial electric vehicle (“EV”) industry innovator and on Aug. 30 the company announced an agreement it expects to be “transformative” in Ideanomics’ pursuit of providing end-to-end services for the commercial EV market. Ideanomics’ planned 100 percent acquisition of Utah’s VIA Motors International, Inc. in an all-stock transaction is expected to grant Ideanomics a vehicle manufacturing element to complement its charging technologies for “an immediate leadership position in a rapidly growing market” and deliver another revenue path to growth and profitability, Ideanomics CEO Alf Poor said in a morning conference call before market opening Aug. 30. “With Via we’re going to make the vehicles. Through our forced induction charging system with WAVE we’re going to be able to charge [them], through our relationship with [Germany’s Prettl Electronics Automotive] we’re going to be able to have outside battery storage to charge any type of fleets outside of a normal grid, and many other aspects, [to create a] complete ecosystem for Ideanomics,” Board Executive Chairman Shane McMahon said during the conference call (https://ibn.fm/3jcXs). Via will make electric commercial vehicles including Class 2 through Class 5 cargo vans, trucks, and buses. The company’s CEO is Bob Purcell, who led the General Motors (“GM”) electric vehicle business in the 1990s and is known as “the father of the legendary GM EV1,” which was the first mass-produced EV. “We were the car that started it all. … I was very proud of my group,” Purcell said in a Barron’s interview about the deal (https://ibn.fm/7lT7v). “We invented that technology … things like torque vector control for motors, battery management systems…none of that existed before the EV1.” The agreement cements Ideanomics as a made-in-America brand and values VIA at $450 million, according to the news release announcing the agreement (https://ibn.fm/lS950). Poor told investors during the conference call that revenue forecasts for the acquisition will be announced in the near future as part of the proxy for shareholders. Under the terms of the agreement, VIA shareholders will receive about 162 million shares of Ideanomics common stock after the application of certain purchase price adjustments, leaving VIA shareholders with ownership of about 25 percent of the combined company. Ideanomics is separately advancing $50 million of financing to VIA in the form of a secured convertible note, according to the news release. Production is planned for 2023, according to Barron’s. “What they needed was a partner that could help them, allow them to focus on execution. Because execution is going to be the difference between who gets market share and who doesn’t,” Poor said. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs
• The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy
• Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible experience
• Investment banking services provider, Ladenburg Thalmann & Co., announced on Aug. 26 that it has initiated coverage on Tryp with a “buy” rating

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is approaching the launch of its phase 2a clinical trial that will use synthetic psilocybin (a psychedelic drug derived from certain mushrooms) in combination with psychotherapy for a select class of overeating disorders. Tryp has continued to execute on its mission to develop successful treatments with increased efficacy for medical conditions with high unmet needs. The phase 2a trial, to be conducted at the University of Florida (“UF”), will determine safety and efficacy of psilocybin on hyperphagia — a condition in which the patients never feel full, so they are continually wanting to eat. “The research we’re actually going to be doing at the University of Florida with psilocybin is focusing on a little bit more intense problems than just eating disorders,” said pediatric eating disorders expert Dr. Jennifer Miller, who will be the trial’s principal investigator, during an interview with The Dales Report in May (https://ibn.fm/XDAVY). “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders … for treatment of a select chronic eating disorder called Prader-Willi Syndrome (‘PWS’).” The hyperphagia trial will also target hypothalamic obesity eating disorder — the result of the removal of a brain tumor — and binge eating disorder. TRP-8802, an off-the-shelf synthetic psilocybin active pharmaceutical ingredient (“API”) will aim to shake up the clinical thinking on how to deal with such neurological conditions and prepare Tryp for further studies using their novel, trademarked drug candidate, TRP-8803. “All of the currently available approved obesity and eating disorder medications are daily medications: you stop taking them, you stop having the efficacy,” Miller said. “Our hope is with psilocybin, … (that) once- or twice-a-year treatments will allow these neural networks to rewire themselves and provide a more chronic treatment, which doesn’t exist right now. … None of the currently available treatments or even past available treatments touch their appetite and fullness.” On Aug. 24, Tryp announced that psychedelic therapy educational platform partner Fluence, has completed the training of the psychotherapists who will be involved in the phase 2a trial by assisting and overseeing dosing sessions of the psychedelics (https://ibn.fm/eCpNN). “Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the news release states. “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming phase 2a clinical trial for eating disorders. … Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists.” To ensure the scientific viability of the trials, it is important to establish definitive guidelines and training to minimize variability and grant the patients the best possible experience. The training will also be adapted to subsequent clinical trials, such as using Tryp’s API to treat fibromyalgia and other chronic pain indications. Tryp’s efforts have caught the attention of investment banking and capital markets products and services provider Ladenburg Thalmann & Co. Inc., which serves investors who are specifically focused on health care and life sciences companies. Ladenburg Thalmann announced on Aug. 26 that it had initiated coverage on Tryp with a buy rating (https://ibn.fm/9aFSD). In its research note, Ladenburg noted that psychedelics have recently outperformed approved prescription treatments for major depressive disorder and posttraumatic stress disorder, leading to the advisement that psilocybin-assisted psychotherapy may provide an appropriate response for helping people with eating disorders “benefit from a disconnect of the brain’s neural connections, allowing for new connections and behaviors distinct from current memories and feelings.” For more information on Tryp Therapeutics, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• AmpliTech posted $1,024,410 in total revenue for Q2’21, a 55% increase from the same period in 2020
• It also announced having paid off $1 million in debt while securing $0.2 million in SBA loan forgiveness
• The company also purchased $0.4 million worth of scientific equipment to enhance product development and testing
• The first half of 2021 also saw AmpliTech complete its financial recapitalization and Nasdaq up-listing, thereby realizing a working capital of $29.8 million
• All these achievements are positioning AmpliTech as the key infrastructure provider that supports 5G, satellite and other radio frequency communications infrastructure globally

On August 16, 2021, AmpliTech Group (NASDAQ: AMPG) announced its financial results for the second quarter of 2021 along with the first six months of the 2021 fiscal year (“Q2’21 and 6M’21”). Additionally, the company reviewed its growth outlook, its strides thus far, and some of the key milestones it achieved in the first half of 2021 (https://ibn.fm/7BCnP). Most notably, the company posted a 55% Q2’21 revenue growth compared to Q2’20. Total revenue stood at $1,024,410, up from $660,669 during the same period in 2020. This also represented a 117% growth from Q1’21. AmpliTech also reported that its order backlog as of the date of the announcement was $2.45 million, all in contractual hardware and engineering services, anticipated for delivery over the next three to six months, as opposed to $2.4 million at the close of Q1’21 (https://ibn.fm/7BCnP). The first six months of 2021 were significant for AmpliTech. For starters, the company completed its financial recapitalization and Nasdaq up-listing. This move allowed it to raise working capital of $29.8 million as of June 30 (https://ibn.fm/588HQ). This capital would go into product development, sales and marketing infrastructure investments while also offering the financial strength needed to engage with global customer prospects that were previously out of the company’s reach. As of the close of the first half of the year, the company had paid $1 million in debt and secured $0.2 million in SBA loan forgiveness. AmpliTech also reported having purchased $0.4 million worth of scientific equipment that was meant to enhance product development and testing (https://ibn.fm/7BCnP). It also made a significant strategic investment in its secure LNA chip development joint venture partner SN2N. AmpliTech is an enterprise that designs, develops and manufactures customer radio frequency (“RF”) components for the commercial, SATCOM, space and military markets. Its product line ranges from new offerings for the 5G/6G wireless ecosystem and infrastructure, along with quantum computing supporting the United States’ efforts to reach the coveted position of quantum supremacy. Since it was founded back in 2002, AmpliTech has remained committed to research and development (“R&D”), allowing it to remain at the forefront of emerging technologies globally. So far, 2021 has been a great year for AmpliTech, and its management is confident that the trajectory will carry on for the remainder of the year. While making the announcement, Fawad Maqbool, the president, CTO and CEO of AmpliTech, noted: “Our Q2 results reflect initial benefits of our significantly enhanced position and the gradual return of customer prospects to more normal planning and procurement activity for projects where our low noise amplifier solutions can deliver game-changing performance and ROI.” He further added: “Importantly, our financial recapitalization is allowing AmpliTech to engage for the first time with a range of very large customer prospects that were previously out of our reach (https://ibn.fm/7BCnP).” AmpliTech has attributed the impressive 6M’21 performance on expanding sales force efforts and the growing demand for its low noise signal amplifiers. It hopes to further capitalize on this to achieve even faster and additional growth as time progresses. “We are making strategic investments in product development, sales and marketing, and personnel and infrastructure to better position AmpliTech for hyper-growth opportunities we see across several markets, including satellite communications, the build out of true 5G infrastructure, quantum computing and space exploration,” noted Mr. Maqbool (https://ibn.fm/588HQ). The company projects that there will be an unprecedented growth in the demand for wireless connectivity given the proliferation of smart devices, cloud computing, autonomous vehicles and content streaming in the next several years. Its investments so far position it to take advantage of this growth and assert its position as a key infrastructure provider to support 5G, satellite and other radio frequency communications infrastructure. So far, AmpliTech’s investments are bearing fruit, all while laying the foundation for the company’s further growth in the future. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• The Happy Co.’s Transformation Challenge includes weekly, monthly prizes as well as five grand prize winners.
• Fit & Happy Weight Loss System, available in Vanilla, Mocha and Birthday Cake flavors, includes filling shakes, Energy Caps and a calming nighttime Chill Drink.
• Qualifying posts can be on public Facebook, Instagram, TikTok or Twitter pages.

Sharing Services Global (OTCQB: SHRG) subsidiary The Happy Co. has invited users of its Weight Loss System to share their transformation through social media — and be rewarded for looking better, feeling better and performing better (https://ibn.fm/PPDCs). The Happy Co.’s Transformation Challenge includes weekly and monthly prizes as well as five grand prize winners, who will receive $1,000 each. A leading producer and distributor of nootropic, functional beverage products with a focus on health and wellness, the Happy Company offers a Fit & Happy Weight Loss System in Vanilla, Mocha and Birthday Cake flavors. The system includes filling shakes that block cravings, Energy Caps (capsules) to keep consumers going strong all day and a calming nighttime Chill Drink; also included in the system is a Fit & Happy Weight Loss System guide, pedometer watch and a Happy Shaker bottle for those who qualify (https://ibn.fm/dCp0A). The Transformation Challenge encourages Fit & Happy Weight Loss System users to post videos and photos showing their healthy transformation. The posts can be on public Facebook, Instagram, TikTok or Twitter pages and include one or both of these two hashtags:  #myhappychallenge and #fitandhappychallenge. There is no limit to the numbers of posts a user can upload. A panel of impartial judges will review each post for authenticity, impact and creativity, and five monthly winners will be chosen each month with each winner receiving $100. In addition, five grand prize winners will be selected from throughout the challenge (July through September); grand prize winners receive $1,000 each, with ten additional winners receiving $200. “Don’t be shy,” the company invites. “Show the world. Let them see your smiling face, your glowing skin and your summer body. And tell the world. We want to hear about how these products have positively impacted your life. Got more energy? Go ahead and share. Sleeping better? Put it out there. Let us know who has noticed and how that makes you feel. The world needs more ‘happy’ right now. This is your chance to win big while making a difference.” During the same time period, The Happy Company is also holding a Shake Recipe Challenge. The company is encouraging users to share the creative, delicious things they make with any of the Happy Company shakes, including those available in the Weight Loss System. The rules for this challenge are the same as the Transformation Challenge, except posters should use these two hashtags: #myhappyrecipes and #fitandhappyrecipes. For this contest, five winners will be chosen every month, with each winner receiving $100. The Happy Co. launched in February 2021 and offers functional beverages, capsules, patches and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat and tighten skin, and make users look, feel and perform like a younger person. The products are nootropics, or nutraceutical formulations derived from food sources that provide health benefits above and beyond basic nutritional value. A publicly traded company specializing in the direct-sales sector, Sharing Services Global Corporation is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• FuelPositive’s patent-pending first-of-its-kind system features an entirely non-polluting process of ammonia (“NH3”) production, using 30% less energy than traditional methods
• Carbon-free NH3 contains 65% more hydrogen than highly compressed hydrogen and addresses challenges associated with storing and distributing hydrogen
• Through its proprietary system, which stores hydrogen in carbon-free ammonia, the company is making possible the green hydrogen economy, with hydrogen able to be efficiently used for energy storage, long-distance transportation of energy, as fuel for internal combustion engine vehicles, and for other applications

We’ve all heard about the hydrogen economy. So why isn’t it happening? In 2019, the transportation sector generated 29% of the total greenhouse gas emissions in the United States, the highest of the main economic sectors (https://ibn.fm/Jy6VS). According to 2020 statistics from the U.S. Energy Information Administration (“EIA”), gasoline accounted for 56% of the country’s transportation energy use, while diesel was responsible for 24%. In total, petroleum products accounted for a whopping 90% of the energy use (https://ibn.fm/7h2gQ), demonstrating the heavy reliance on these fossil fuels despite the growing availability of electric vehicles and all the talk about the hydrogen economy. The hydrogen economy envisions a future where carbon-free hydrogen is used for energy storage, long-distance transportation of energy, and as fuel for vehicles and heat generation. With the heightened consciousness around emissions spearheaded by governments setting net-zero greenhouse emission targets, carbon-free “green” hydrogen is emerging as a key piece of the zero-emissions puzzle. As a fuel, hydrogen has no rival — it burns cleanly and produces more power per unit of weight than gasoline or diesel or even lithium-ion batteries. But moving to the hydrogen economy is not as simple as it sounds. There are practical problems that have so far prevented its implementation. FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a company committed to clean energy solutions, is making the green hydrogen economy possible through its proprietary carbon-free ammonia (“NH3”) system. While hydrogen is an ideal energy carrier that can help address numerous energy issues, its use faces several hurdles. Firstly, blue and grey hydrogen production (the only kind today) using the traditional methods is energy intensive and almost entirely relies on fossil fuels. According to the International Energy Agency (“IAE”), about 6% of natural gas and 2% of coal produced globally go into hydrogen production. As a result, it is responsible for about 830 million tons of CO2 emissions per year (https://ibn.fm/NurmL). That is not acceptable since the purpose behind the hydrogen economy is to reduce greenhouse gas emissions. Even when sustainable electricity is used to produce green hydrogen, it is an extremely energy intensive process. Secondly, once produced, hydrogen is extremely volatile. Being lighter than air and even gasoline vapor, hydrogen rapidly rises and disperses upon escaping. This property is compounded by the fact that hydrogen is highly flammable and requires the lowest ignition energy of any fuel (https://ibn.fm/MbHUo), making it a risk for explosions. This, therefore, necessitates an expensive and safe storage in pressurized containers, which unfortunately presents another problem. As a gas, hydrogen must be compressed to extreme pressures to be adequate for transportation use and as a liquid, it boils off at standard temperatures (e.g., a hypothetical car with a full liquid hydrogen tank sitting in your garage on Friday would have an empty tank on Monday due to room-temperature boil-off). What about distribution? Hydrogen is known to embrittle steel pipes, necessitating more expensive, specially engineered pipelines to prevent hydrogen from escaping. Hydrogen is the smallest element on the periodic table. It’s so small it can even work its way in between the crystalline structure of metals, making them brittle and susceptible to cracking and failure. But hydrogen can be transported in chemical carriers, including liquid inorganic carriers such as ammonia. This is where FuelPositive’s carbon-free NH3 comes in. NHHHF’s patent-pending first-of-its-kind system enables the company to produce NH3 without relying on hydrocarbons in a dramatically less expensive process. The system also requires 30% less energy than conventional NH3 production methods. What’s more, carbon-free ammonia, which is made up of about 17.8% hydrogen by weight, also contains a higher volumetric hydrogen density/content than both liquid and compressed hydrogen. FuelPositive puts the figure at 65% more hydrogen than highly compressed hydrogen (https://ibn.fm/Hm4Pc). A 2020 review titled “Ammonia as effective hydrogen storage” observes that the content is 187% higher when liquid ammonia is used (https://ibn.fm/benoS). With storage and distribution infrastructure already in place, NH3 can be transported in tanker trucks, through pipelines and on ships. At the same time, FuelPositive’s in-situ carbon-free NH3 modular production systems can be installed with the end users, reducing the reliance on these unnecessary forms of ammonia distribution. “So, think of ammonia as the perfect carrier of hydrogen, and if the end-user requirement is pure hydrogen, then the safest and most practical way to get that hydrogen where it needs to be is through FuelPositive carbon-free ammonia,” the company concludes. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• PlantX’s operations are firmly anchored on three operational focal points, namely products, distribution and community
• The company is also guided by a growth strategy, under which the e-commerce platform is the main driver of growth
• In a recent press release, PlantX announced the launch of its redesigned Canadian website, powered by Shopify
• According to PlantX Founder Sean Dollinger, the decision to host the e-commerce platform on Shopify is strategic and complements the company’s mission and expansion plans

As a multifaceted marketplace, PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based space by providing consumers with all things plant-based across three main operational focal points — products, distribution and community. Firstly, PlantX offers over 5,000 plant-based products from established and new brands, with more added daily, as well as meal delivery across the United States and Canada. Secondly, it then distributes these products through a powerful, all-encompassing e-commerce ecosystem, along with flagship brick-and-mortar retail stores in high-traffic epicenters around the world. Notably, these stores aim to enhance the company’s e-commerce presence through interactive shopping. Thirdly, PlantX is building a community by leveraging education and collaborations. The company regularly updates its website and YouTube channel (https://www.youtube.com/c/PlantX/videos) with informative resources on plant-based foods and vegan diets, packaged as blog articles, recipe videos, nutritional advice videos, or its video podcast series, currently in its second season. It even has a fitness vertical that builds bridges between people with fitness knowledge and those who need it. With its operations firmly anchored on these three points, PlantX has set sights on growth. “The growth strategy for PlantX is surprisingly simple. The e-commerce platform is the main driver of growth. By offering the widest possible array of plant-based products, PlantX is positioned to be the online destination for all plant-based needs and desires,” says PlantX CEO Lorne Rapkin. PlantX recently announced the launch of its redesigned Canadian website, powered by Shopify (https://ibn.fm/mvXl0). You can access the website at www.PlantX.ca. “The company’s redesigned Canadian website was developed to better represent the company’s brand strategy, promote community engagement, improve customer satisfaction, and increase business reach,” explains the press release. The website now features a refreshed and modern design, simplified navigation, and improved search tools and functionality to enhance the overall user experience and brand impact. At the same time, it still offers access to PlantX’s informative resources, namely its podcast series and blog articles. Aiming to maximize the impact of the new platform, PlantX has also engaged UI/UX specialists to improve the website’s performance through better navigation speed and optimized conversion rates. The company intends to launch a new United States website on the Shopify platform later this year. Through its e-commerce platform, the company can actualize its plans to expand globally, to Australia, Latin America, Europe, and Asia. By leveraging the Shopify embedded features, the company will be able to easily clone its current Canadian model and launch additional websites in other countries with a click of a button. When launching in a new country, the company will be able to simply duplicate the PlantX theme and website features on Shopify, and then use the cloned platform to add products relevant to the country of interest. The automation of the company’s e-commerce expansion activity will increase its business effectiveness and allow PlantX to focus its efforts on curating the best plant-based products and educational resources for its customers, therefore boosting community engagement and satisfaction. “The decision to transition to Shopify as the main e-commerce platform to host the PlantX online presence is a strategic move that complements the company’s mission and expansion plans,” said PlantX Founder Sean Dollinger. “By leveraging the Shopify embedded features, PlantX will be able to replicate its current Canadian model and launch additional websites in other countries.” PlantX is a one-stop shop for all things plant-based. It offers consumers an efficient e-commerce experience, interactive brick-and-mortar stores, and a home delivery system for products, recipes, meals, and more. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Avricore seeks to build the world’s largest network of diagnostic centres in pharmacy.
• Through its flagship platform, HealthTab(TM), the company is simplifying patients’ lives through easy access to point-of-care testing
• Through innovation, technology and partnering with key players in the industry, Avricore is allowing easy access to critical health information for patients and doing so in a convenient way for them. This, it believes, is the future of healthcare

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator committed to acquiring and developing early-stage technologies that seek to grow and push pharmacy forward. Since its inception, this Vancouver-based enterprise has stayed true to its mission to become the world’s largest health data company. This is evidenced by its move to innovate and leverage specific point-of-care technologies within its community of pharmacies. Avricore’s flagship platform, HealthTab(TM), impacts the healthcare sector mainly by simplifying patients’ lives with easy access to point-of-care testing. With HealthTab, Avricore can offer pharmacies complete turnkey and point-of-care rapid testing systems covering both software and hardware (https://ibn.fm/GN0Tk). Consequently, customers can quickly and conveniently check for markets associated with conditions such as heart disease, diabetes or any other conditions, with a simple finger-prick blood test and under the guidance of a pharmacist. “HealthTab is a way for anybody to get access to important health information in a way that’s convenient for them, and at a time that’s convenient for them,” noted Rodger Seccombe, the Chief Technology Officer (“CTO”) at Avricore (https://ibn.fm/fo4Sk). It is one thing to have the technology and expertise to test patients quickly, but it is a whole other thing to get it to the intended patients. This is why Avricore has resorted to partnerships in a decentralization move that facilitates its growth and makes its technology and services accessible to as many people as possible. So far in 2021, Avricore has secured a distribution agreement with Abbott Canada, the first of its type for a health-data company. Avricore also entered into a master agreement with Shoppers Drug Mart in Canada, giving its service access to over 1,300 stores, a move that so far is proving successful. With the point-of-care diagnostics market projected to grow to $50.6 billion by 2025, Avricore is positioning itself to grow with it and arguably become a leader in the industry (https://ibn.fm/ySU2M). Currently, Avricore earns its revenue from data collection, equipment leasing, API integration, the sale of consumables associated with testing, along with screening tests. As time progresses, and with the investments and partnerships it is forging along the way, the company looks forward to forming an in-pharmacy network. This would allow it to secure steady revenues and collect real-world data that would enable researchers to quickly and efficiently examine health data trends, eventually transforming that into another source of income. The COVID-19 pandemic presented a massive growth for Avricore’s market opportunity. For starters, the public learned the positive impacts of early detection and rapid testing. Avricore’s Chief Executive Officer (“CEO”), Hector Bremner, acknowledged this opportunity, even citing rapid testing and early detection as “The future of pharmacy (https://ibn.fm/DJtmQ).” With different companies also recognizing this opportunity, Avricore has managed to stay one step ahead by bringing its services closer to the people with its pharmacies. “Yes, you need good instruments, but you need a whole system around that instrument,” noted Seccombe. “That’s where we’ve come in and developed a real out-of-box solution that works for pharmacies (https://ibn.fm/DJtmQ).” All the milestones achieved by Avricore throughout 2021, including the Ellerca Health Partnership, HealthTab rollout and the Shoppers Drug Mart agreement, among others, are representative of an enterprise that is constantly pushing the envelope in the healthcare sector. Avricore is staying true to its mission, and because of this, it is defining the future of healthcare. To learn more about the company, please visit www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• SRAX offers a premier investor intelligence and communications platform branded Sequire for clients to track investors’ behavior and trends, and engage shareholders
• SRAX is hosting its first Sequire EdTech Conference on September 13, 2021, which will include corporate presentations, keynote speakers and more
• EdTech is a thriving marketplace forecast to grow from $85 billion in 2020 to $382 billion in 2028

Technology continues to be the hottest market around as evidenced by the NASDAQ Composite Index steadily setting new record highs as it charts a course toward 15,500. Within that market, education technology, or EdTech for short, is shining bright with SRAX (NASDAQ: SRAX) this month bringing together some of its stars in the first ever Sequire EdTech Conference, a one-day investor event featuring prominent virtual work and remote learning companies. Sequire is SRAX’s premier investor intelligence and communications software-as-a-service (“SaaS”) platform that allows companies a means to track their investors’ behaviors and trends. Armed with this insight, public companies are in a better-informed position to engage current and potential investors across different marketing channels. The conference touches multiple value points for SRAX by featuring a burgeoning industry as a key opinion leader, showing off its platform to potential clients and investors, and putting a spotlight on public companies in the EdTech space. Since COVID-19, there has been an existing trend for remote work and “non-traditional” education for at-home learning. Programs like Google Classroom and Zoom accelerated while schools were shuttered. With the resilient virus and its latest variant (delta) still prominent, schools across the country are once again shutting down, at least temporarily, as the nation tries to slow viral spread. Ahead of the new school year beginning, Dr. Richard Besser, a former official for the Centers for Disease Control and Prevention, told Today that he expects the fall season to again be challenging for schools (https://ibn.fm/8xBxt). Against this backdrop, “there’s never been a more important time to invest in the companies making strides in remote workplaces and classrooms” reads the Sequire EdTech Conference website. The conference, which is being held from 11:30 AM ET – 5:30 PM ET on Monday, Sept. 13, 2021, will include presentations from over 10 publicly traded companies, one-on-one meetings, and panels with industry experts on the future of work and education. According to Grand View Research, there are multiple catalysts that will undergird 19.9% compound annual growth for the global EdTech market from $84.49 billion in 2020 to $382.23 billion in 2028 (https://ibn.fm/e3B5f). The research firm sees, amongst other things, the integration of emerging artificial intelligence (“AI”), augmented (“AR”) and virtual reality (“VR”), and blockchain solutions into EdTech as growth drivers. One speaker at the Sequire EdTech Conference is Dr. Ann Marie Sastry, president and CEO of Amesite, a premier sponsor of the event and an award-winning artificial intelligence software company focused on improving learning. Amesite’s AI-driven, online learning platform, has been named the winner of the 2020 Best and Brightest Companies to Work For in the Nation and 2020 National Best and Brightest in Wellness. “EdTech has changed forever, and corporations have quickly changed the way they are training their employees. There is a great group of companies that are transforming this sector, many of which we have the pleasure of hosting at this event,” said Christopher Miglino, founder and CEO of SRAX, in a press release on the event. For more information, please visit the SRAX website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX